Disproportionality Analyses | List of Frontiers open access articles

Review

Published on 26 Jan 2024

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

in Advanced Methods in Pharmacovigilance and Pharmacoepidemiology

Paola Maria Cutroneo
Daniele Sartori
Marco Tuccori
Salvatore Crisafulli
Vera Battini
Carla Carnovale
Concetta Rafaniello
Annalisa Capuano
Elisabetta Poluzzi
Ugo Moretti

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2023.1323057

22,101 views
137 citations

Brief Research Report

Published on 28 May 2021

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances

in Drugs Outcomes Research and Policies

Charles Khouri
Thuy Nguyen
Bruno Revol
Marion Lepelley
Antoine Pariente
Matthieu Roustit
Jean-Luc Cracowski

Frontiers in Pharmacology

doi 10.3389/fphar.2021.668765

6,618 views
41 citations

Original Research

Published on 09 Jan 2024

Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system

in Inflammation Pharmacology

Chunyan Wei
Wanhong Yin
Tingting Hu
Jingyi Zhang
Huifang Dan
Bin Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1323240

4,026 views
3 citations

Original Research

Published on 09 Jun 2020

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

in Drugs Outcomes Research and Policies

Rosanna Ruggiero
Federica Fraenza
Cristina Scavone
Gabriella di Mauro
Raffaele Piscitelli
Annamaria Mascolo
Carmen Ferrajolo
Concetta Rafaniello
Liberata Sportiello
Francesco Rossi

Frontiers in Pharmacology

doi 10.3389/fphar.2020.00830

7,241 views
33 citations

Original Research

Published on 23 May 2022

Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review

in Intensive Care Medicine and Anesthesiology

Mathieu Jozwiak
Guillaume Geri
Driss Laghlam
Kevin Boussion
Charles Dolladille
Lee S. Nguyen

Frontiers in Medicine

doi 10.3389/fmed.2022.826446

21,925 views
27 citations

Perspective

Published on 27 Nov 2024

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline

in Pharmacoepidemiology

Michele Fusaroli
Francesco Salvo
Charles Khouri
Emanuel Raschi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1488725

4,513 views
9 citations

Original Research

Published on 21 Jun 2024

A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system

in Renal Pharmacology

Jingyi Zhang
Yuting Guo
Chunyan Wei
Yu Yan
Huifang Shan
Bin Wu
Fengbo Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1363501

3,887 views
4 citations

Original Research

Published on 10 Jul 2024

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

in Drugs Outcomes Research and Policies

Zheng Zhang
Qianzhi Yang
Minghao Chen
Wah Yang
Yuping Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385651

5,896 views
2 citations

Original Research

Published on 02 Oct 2023

Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study

in Drugs Outcomes Research and Policies

Zhenzhen Deng
Shengfeng Wang
Cuifang Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1197470

12,132 views
12 citations

Original Research

Published on 09 Jan 2026

Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data

in Neuropharmacology

Tingting Yang
Xiaoxiao Wu
Xueliang Yi
Chunlin Xiang
Yinping Yang
Chen Yang
Xiaoxia Zheng
Yuhong Han
Yiping Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1737359

1,710 views

Original Research

Published on 11 Nov 2025

HPV vaccine-related thyroid adverse events: temporal patterns and reporting trends

in Pharmacoepidemiology

Liying Song
Jingkai Di
Jiaolin Fan
Rongrong Xi
Siyu Liang
Guosheng Duan
Yuanzheng Ding
Shuai Hao
Jing Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1664697

4,495 views

Original Research

Published on 10 Jul 2024

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023

in Drugs Outcomes Research and Policies

Jinger Lin
Xiangqi Chen
Min Luo
Qianwei Zhuo
Haosong Zhang
Nuo Chen
Yunqian Zhuo
Yue Han

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1420478

5,844 views
12 citations

Original Research

Published on 10 Nov 2022

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System

in Pharmacoepidemiology

Takamasa Sakai
Chiyo Mori
Fumiko Ohtsu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1063625

6,124 views
18 citations

Original Research

Published on 11 Nov 2025

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod

in Pharmacoepidemiology

Yingxiu Wu
Wei Ke
Huibiao Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1693090

2,997 views
4 citations

Original Research

Accepted on 09 Mar 2026

Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis

in Pharmacoepidemiology

Hongchun Qiu
Yong Wang
Qian Liu
Jing Xu
Fei Yang
Meiyan Wang
Haoxiang Lu
Jie Wu
Ao Zhang
Xingli Zhang

Frontiers in Pharmacology

135 views

Original Research

Published on 29 Aug 2025

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study

in Respiratory Pharmacology

Xu Miao
Yuan Liu
Xiaoqin Li
Rong Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1652750

3,286 views
6 citations

Articles

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances

Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline

A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study

Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data

HPV vaccine-related thyroid adverse events: temporal patterns and reporting trends

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod

Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study